Voranigo is the first targeted therapy in almost 25 years to be approved by the FDA for grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
FDA Approves Servier’s Voranigo for Grade 2 IDH-Mutant Glioma